Completed OBSERVATIONAL NCT01674972

Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

Sponsor: University Hospital, Basel, Switzerland

Conditions Non Alcoholic Fatty Liver Disease Non Alcoholic Steatohepatitis

Interventions Oral glucose tolerance test

Updated 9 times since 2017 Last updated: Aug 24, 2012 Started: Jan 31, 2011 Primary completion: Apr 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis and is currently completed. University Hospital, Basel, Switzerland leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 4 earlier versions

May 2018 — Nov 2020 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Basel, Switzerland

Data source: University Hospital, Basel, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland